Home
/ Alnylam
/ Competitors

Alnylam Competitors and Similar CompaniesClear all

Alnylam's competitors and similar companies include Reata Pharmaceuticals, Sorrento Therapeutics, Moderna and Regulus Therapeutics.

	Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.	Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.	Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.	Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Founding Date	Founding Date 2002	Founding Date 2002	Founding Date 2006	Founding Date 2010	Founding Date 2007
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech healthtech pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more	Locations Plano, US HQ Irving, US Plano, US	Locations San Diego, US HQ San Diego, US	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more	Locations San Diego, US HQ
Employees	Employees 1,32324% increase	Employees 3217% decrease	Employees 31019% decrease	Employees 5,60044% increase	Employees 2462% decrease
Valuation ($)	Valuation ($) 36.5 b	Valuation ($) 6.6 b	Valuation ($) 1.5 m	Valuation ($) 21.2 b	Valuation ($) 105.4 m
Financial
Revenue (est.)	Revenue (est.) $1.8b (FY, 2023)	Revenue (est.) $2.2m (FY, 2022)	Revenue (est.) $62.8m (FY, 2022)	Revenue (est.) $6.8b (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods $268.2m (FY, 2023)	Cost of goods N/A	Cost of goods N/A	Cost of goods $4.7b (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit $1.6b (FY, 2023)	Gross profit N/A	Gross profit N/A	Gross profit $2.2b (FY, 2023)	Gross profit N/A
Net income	Net income ($440.2m) (FY, 2023)	Net income ($311.9m) (FY, 2022)	Net income ($577.8m) (FY, 2022)	Net income ($4.7b) (FY, 2023)	Net income ($30m) (FY, 2023)
Operating ⚠
Patents Issued	Patents Issued N/A	Patents Issued 240 (FY, 2016)	Patents Issued N/A	Patents Issued 270 (FY, 2020)	Patents Issued 300 (FY, 2016)
Funding
Total funding raised	Total funding raised $ 1.5b	Total funding raised $ 468.9m	Total funding raised $ 42.6m	Total funding raised $ 1.8b	Total funding raised $ 10m